Three Covid vaccines have now been approved for use in the UK. The Moderna jab was given the green light on Friday, making it the third to be approved in the country. Here is everything you need to know about the three vaccines: Moderna The Moderna vaccine was just approved today for use in the UK. It was made in the US and Americans have rolled it out already. Although the UK has recently bought 17 million doses, it won’t be available until spring. It’s quite similar to the Pfizer vaccine in how it works as well as the protection level that it offers. It injects part of the virus’ genetic code to generate an immune response in the body against Covid-19, and after receiving two doses, four weeks apart, it offers 95% protection against the virus.
Science’
s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.
As the COVID-19 pandemic surges, fueled in some places by new, fast-spreading variants, officials and public health experts are debating strategies for stretching limited supplies of vaccines. And vaccinemakers have been caught in the middle. Over the past week, one has endorsed a U.K. decision to extend the interval between an initial priming vaccine dose and the booster shot to up to 12 weeks. Another has pushed back. The maker of a third COVID-19 vaccine has so far stayed silent on yet another plan, floated by the scientist heading the U.S. COVID-19 vaccine effort but opposed by the U.S. Food and Drug Administration (FDA), to stretch supply by halving both its prime and booster doses.
RPS backs changes to interval between COVID-19 vaccination doses pharmaceutical-journal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-journal.com Daily Mail and Mail on Sunday newspapers.
Science s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation
Last-minute vaccine dosing changes that could gamble away proven COVID-19 protection and undermine public trust. Controversial approvals without any efficacy data. Vaccinemakers at odds with countries hosting their clinical trials. The COVID-19 vaccine landscape keeps changing almost daily, simultaneously raising hopes and triggering confusion and scientific debates. “It s crazy,” says vaccine researcher John Moore of Weill Cornell Medicine. “Every morning, it s just, ‘What s going on?’”
Over the past few weeks, COVID-19 vaccines developed in the United Kingdom, China, and India moved toward widespread rollout, offering new weapons in the face of fast-spreading viral variants that threaten to deepen the crisis (see p. 108). But many came with controversies, and U.K. regulators sparked a debate when they endorsed a sharp departure from the expected dosing schedule for a new